Drug intelligence / Profile preview

MYO3

Development stage: Preclinical
Lead developer: Myocea
Modality: Small Molecules
Administration: Oral

Overview

MYO3 is a **preclinical small-molecule** drug candidate from **Myocea** being developed for **Spinal Muscular Atrophy**. In the company pipeline, it is described as targeting **Network 3**, a program related to SMA-associated skeletal muscle and neuromuscular junction biology, but the precise molecular target and pharmacologic mechanism have not been publicly disclosed. Based on the available pipeline information, MYO3 appears to be an internal discovery-stage SMA asset rather than a clinically characterized or branded medicine.

Other names: Myocea Network 3 small molecule

Targets

TSPAN31 (N-acetylneuraminic acid synthase)

Beyond the preview

Go deeper on MYO3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MYO3.

Explore the full profile